Celyad publishes additional pre-clinical data in support of THINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Celyad Announces First Quarter 2017 Business Update

Celyad Announces First Quarter 2017 Business Update

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Celyad initiates second dose escalation in THINK trial in first US patient

Celyad initiates second dose escalation in THINK trial in first US patient

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017